Free Trial

Vera Therapeutics (VERA) Stock Price, News & Analysis

Vera Therapeutics logo
$22.63 +0.34 (+1.53%)
Closing price 07/23/2025 04:00 PM Eastern
Extended Trading
$22.79 +0.16 (+0.71%)
As of 07/23/2025 05:20 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Vera Therapeutics Stock (NASDAQ:VERA)

Key Stats

Today's Range
$22.29
$23.30
50-Day Range
$18.87
$32.00
52-Week Range
$18.53
$51.61
Volume
648,898 shs
Average Volume
1.00 million shs
Market Capitalization
$1.44 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$65.00
Consensus Rating
Buy

Company Overview

Vera Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
82nd Percentile Overall Score

VERA MarketRank™: 

Vera Therapeutics scored higher than 82% of companies evaluated by MarketBeat, and ranked 159th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Vera Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.10, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Vera Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Vera Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Vera Therapeutics are expected to decrease in the coming year, from ($2.89) to ($3.13) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Vera Therapeutics is -7.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Vera Therapeutics is -7.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Vera Therapeutics has a P/B Ratio of 2.49. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Vera Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    0.23% of the float of Vera Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Vera Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Vera Therapeutics has recently decreased by 98.33%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Vera Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Vera Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.23% of the float of Vera Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Vera Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Vera Therapeutics has recently decreased by 98.33%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Vera Therapeutics has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.62 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Vera Therapeutics this week, compared to 6 articles on an average week.
  • Search Interest

    Only 3 people have searched for VERA on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
  • MarketBeat Follows

    13 people have added Vera Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 30% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Vera Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,277,598.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    16.30% of the stock of Vera Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    99.21% of the stock of Vera Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Vera Therapeutics' insider trading history.
Receive VERA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vera Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VERA Stock News Headlines

Trump’s $100 Trillion Land Rush Is On
What Is "The US: IPO"? You won't hear this on CNBC... but the government may soon open up hundreds of trillions in oil, gas, lithium, and land rights. Whitney Tilson breaks it all down, and shows how everyday Americans can grab a stake. His urgent new briefing explains "The US: IPO"... and how to get in before the looming federal deadline.
See More Headlines

VERA Stock Analysis - Frequently Asked Questions

Vera Therapeutics' stock was trading at $42.29 on January 1st, 2025. Since then, VERA shares have decreased by 46.5% and is now trading at $22.63.

Vera Therapeutics, Inc. (NASDAQ:VERA) announced its quarterly earnings data on Thursday, May, 8th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by $0.06.

Vera Therapeutics (VERA) raised $66 million in an IPO on Friday, May 14th 2021. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen and Evercore ISI served as the underwriters for the IPO.

Top institutional investors of Vera Therapeutics include Platinum Investment Management Ltd. (0.25%), J. Safra Sarasin Holding AG (0.05%), GC Wealth Management RIA LLC (0.02%) and Perigon Wealth Management LLC (0.02%). Insiders that own company stock include Commodore Capital Lp, Patrick G Enright, Sofinnova Venture Partners X,, Carlyle Group Inc, Maha Katabi, Marshall Fordyce, Beth C Seidenberg, Sean Grant, Joseph R Young, Joanne Curley and Celia Lin.
View institutional ownership trends
.

Shares of VERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vera Therapeutics investors own include CRISPR Therapeutics (CRSP), Pure Storage (PSTG), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE) and Arista Networks (ANET).

Company Calendar

Last Earnings
5/08/2025
Today
7/24/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VERA
CIK
1831828
Fax
N/A
Employees
40
Year Founded
N/A

Price Target and Rating

High Price Target
$100.00
Low Price Target
$26.00
Potential Upside/Downside
+187.2%
Consensus Rating
Buy
Rating Score (0-4)
3.10
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.00)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$152.15 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-40.59%
Return on Assets
-34.54%

Debt

Debt-to-Equity Ratio
0.10
Current Ratio
27.68
Quick Ratio
27.68

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$9.08 per share
Price / Book
2.49

Miscellaneous

Outstanding Shares
63,770,000
Free Float
53,379,000
Market Cap
$1.44 billion
Optionable
Optionable
Beta
1.19

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

This page (NASDAQ:VERA) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners